ID   RIR1_HUMAN              Reviewed;         792 AA.
AC   P23921; Q9UNN2;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-1992, sequence version 1.
DT   10-MAY-2017, entry version 179.
DE   RecName: Full=Ribonucleoside-diphosphate reductase large subunit;
DE            EC=1.17.4.1;
DE   AltName: Full=Ribonucleoside-diphosphate reductase subunit M1;
DE   AltName: Full=Ribonucleotide reductase large subunit;
GN   Name=RRM1; Synonyms=RR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=1840662; DOI=10.1093/nar/19.13.3741;
RA   Parker N.J., Begley C.G., Fox R.M.;
RT   "Human M1 subunit of ribonucleotide reductase: cDNA sequence and
RT   expression in stimulated lymphocytes.";
RL   Nucleic Acids Res. 19:3741-3741(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary carcinoma;
RX   PubMed=1627826; DOI=10.3109/10425179209020807;
RA   Pavloff N., Rivard D., Masson S., Shen S.-H., Mes-Masson A.-M.;
RT   "Sequence analysis of the large and small subunits of human
RT   ribonucleotide reductase.";
RL   DNA Seq. 2:227-234(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9933563; DOI=10.1006/geno.1998.5659;
RA   Bepler G., O'Briant K.C., Kim Y.-C., Schreiber G., Pitterle D.M.;
RT   "A 1.4-Mb high-resolution physical map and contig of chromosome
RT   segment 11p15.5 and genes in the LOH11A metastasis suppressor
RT   region.";
RL   Genomics 55:164-175(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.
RC   TISSUE=Placenta;
RX   PubMed=8188248; DOI=10.1006/geno.1994.1017;
RA   Parker N.J., Begley C.G., Fox R.M.;
RT   "Human R1 subunit of ribonucleotide reductase (RRM1): 5' flanking
RT   region of the gene.";
RL   Genomics 19:91-96(1994).
RN   [6]
RP   ENZYME REGULATION.
RX   PubMed=1867633; DOI=10.1016/0006-2952(91)90033-2;
RA   Harrington J.A., Spector T.;
RT   "Human ribonucleotide reductase. Activation and inhibition by analogs
RT   of ATP.";
RL   Biochem. Pharmacol. 42:759-763(1991).
RN   [7]
RP   INTERACTION WITH RRM2B.
RX   PubMed=12615712;
RA   Xue L., Zhou B., Liu X., Qiu W., Jin Z., Yen Y.;
RT   "Wild-type p53 regulates human ribonucleotide reductase by protein-
RT   protein interaction with p53R2 as well as hRRM2 subunits.";
RL   Cancer Res. 63:980-986(2003).
RN   [8]
RP   CATALYTIC ACTIVITY, SUBUNIT, AND ENZYME REGULATION.
RX   PubMed=16376858; DOI=10.1016/j.bbrc.2005.12.019;
RA   Qiu W., Zhou B., Darwish D., Shao J., Yen Y.;
RT   "Characterization of enzymatic properties of human ribonucleotide
RT   reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and
RT   p53R2 subunits.";
RL   Biochem. Biophys. Res. Commun. 340:428-434(2006).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-17 AND LYS-376, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-751, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   ENZYME REGULATION, MUTAGENESIS OF ASP-57, AND INTERACTION WITH AHCYL1.
RX   PubMed=25237103; DOI=10.1126/science.1251550;
RA   Arnaoutov A., Dasso M.;
RT   "Enzyme regulation. IRBIT is a novel regulator of ribonucleotide
RT   reductase in higher eukaryotes.";
RL   Science 345:1512-1515(2014).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 75-742 IN COMPLEX WITH
RP   ALLOSTERIC EFFECTOR ATP AND MAGNESIUM IONS.
RX   PubMed=21336276; DOI=10.1038/nsmb.2007;
RA   Fairman J.W., Wijerathna S.R., Ahmad M.F., Xu H., Nakano R., Jha S.,
RA   Prendergast J., Welin R.M., Flodin S., Roos A., Nordlund P., Li Z.,
RA   Walz T., Dealwis C.G.;
RT   "Structural basis for allosteric regulation of human ribonucleotide
RT   reductase by nucleotide-induced oligomerization.";
RL   Nat. Struct. Mol. Biol. 18:316-322(2011).
CC   -!- FUNCTION: Provides the precursors necessary for DNA synthesis.
CC       Catalyzes the biosynthesis of deoxyribonucleotides from the
CC       corresponding ribonucleotides.
CC   -!- CATALYTIC ACTIVITY: 2'-deoxyribonucleoside diphosphate +
CC       thioredoxin disulfide + H(2)O = ribonucleoside diphosphate +
CC       thioredoxin. {ECO:0000269|PubMed:16376858}.
CC   -!- ENZYME REGULATION: Under complex allosteric control mediated by
CC       deoxynucleoside triphosphates and ATP binding to separate
CC       specificity and activation sites on the M1 subunit. The type of
CC       nucleotide bound at the specificity site determines substrate
CC       preference. It seems probable that ATP makes the enzyme reduce CDP
CC       and UDP, dGTP favors ADP reduction and dTTP favors GDP reduction.
CC       Stimulated by ATP and inhibited by dATP binding to the activity
CC       site, the dATP inhibition is mediated by AHCYL1 which stabilizes
CC       dATP in the site. {ECO:0000269|PubMed:16376858,
CC       ECO:0000269|PubMed:1867633, ECO:0000269|PubMed:25237103}.
CC   -!- PATHWAY: Genetic information processing; DNA replication.
CC   -!- SUBUNIT: Heterodimer of a large and a small subunit. Heterodimer
CC       with small subunit RRM2 or RRM2B. The heterodimer with RRM2 has
CC       higher catalytic activity than the heterodimer with RRM2B.
CC       Interacts with AHCYL1 which inhibits its activity.
CC       {ECO:0000269|PubMed:16376858, ECO:0000269|PubMed:21336276,
CC       ECO:0000269|PubMed:25237103}.
CC   -!- INTERACTION:
CC       P31350:RRM2; NbExp=3; IntAct=EBI-717006, EBI-2339245;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- MISCELLANEOUS: Two distinct regulatory sites have been defined:
CC       the specificity site, which controls substrate specificity, and
CC       the activity site which regulates overall catalytic activity. A
CC       substrate-binding catalytic site, located on M1, is formed only in
CC       the presence of the second subunit M2.
CC   -!- MISCELLANEOUS: The level of the enzyme activity is closely
CC       correlated with the growth rate of a cell and appears to vary with
CC       the cell cycle.
CC   -!- SIMILARITY: Belongs to the ribonucleoside diphosphate reductase
CC       large chain family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ribonucleotide reductase entry;
CC       URL="https://en.wikipedia.org/wiki/Ribonucleotide_reductase";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RRM1ID42174ch11p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X59543; CAA42118.1; -; mRNA.
DR   EMBL; X59617; CAA42180.1; -; mRNA.
DR   EMBL; AF107045; AAD37491.1; -; Genomic_DNA.
DR   EMBL; BC006498; AAH06498.1; -; mRNA.
DR   EMBL; L10342; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS7750.1; -.
DR   PIR; S16680; S16680.
DR   RefSeq; NP_001024.1; NM_001033.4.
DR   RefSeq; NP_001304993.1; NM_001318064.1.
DR   RefSeq; NP_001304994.1; NM_001318065.1.
DR   UniGene; Hs.445705; -.
DR   PDB; 2WGH; X-ray; 2.30 A; A/B=75-742.
DR   PDB; 3HNC; X-ray; 2.41 A; A/B=1-792.
DR   PDB; 3HND; X-ray; 3.21 A; A/B=1-792.
DR   PDB; 3HNE; X-ray; 3.11 A; A/B=1-792.
DR   PDB; 3HNF; X-ray; 3.16 A; A/B=1-792.
DR   PDB; 4X3V; X-ray; 3.70 A; A/B=1-792.
DR   PDB; 5D1Y; X-ray; 9.01 A; A/B=1-792.
DR   PDBsum; 2WGH; -.
DR   PDBsum; 3HNC; -.
DR   PDBsum; 3HND; -.
DR   PDBsum; 3HNE; -.
DR   PDBsum; 3HNF; -.
DR   PDBsum; 4X3V; -.
DR   PDBsum; 5D1Y; -.
DR   ProteinModelPortal; P23921; -.
DR   SMR; P23921; -.
DR   BioGrid; 112154; 37.
DR   DIP; DIP-24233N; -.
DR   IntAct; P23921; 12.
DR   MINT; MINT-1406473; -.
DR   STRING; 9606.ENSP00000300738; -.
DR   BindingDB; P23921; -.
DR   ChEMBL; CHEMBL1830; -.
DR   DrugBank; DB00242; Cladribine.
DR   DrugBank; DB00631; Clofarabine.
DR   DrugBank; DB01073; Fludarabine.
DR   DrugBank; DB05420; gallium maltolate.
DR   DrugBank; DB00441; Gemcitabine.
DR   DrugBank; DB01005; Hydroxyurea.
DR   DrugBank; DB05003; Imexon.
DR   GuidetoPHARMACOLOGY; 2630; -.
DR   iPTMnet; P23921; -.
DR   PhosphoSitePlus; P23921; -.
DR   SwissPalm; P23921; -.
DR   BioMuta; RRM1; -.
DR   DMDM; 132608; -.
DR   EPD; P23921; -.
DR   MaxQB; P23921; -.
DR   PaxDb; P23921; -.
DR   PeptideAtlas; P23921; -.
DR   PRIDE; P23921; -.
DR   DNASU; 6240; -.
DR   Ensembl; ENST00000300738; ENSP00000300738; ENSG00000167325.
DR   GeneID; 6240; -.
DR   KEGG; hsa:6240; -.
DR   UCSC; uc001lyw.5; human.
DR   CTD; 6240; -.
DR   DisGeNET; 6240; -.
DR   GeneCards; RRM1; -.
DR   HGNC; HGNC:10451; RRM1.
DR   HPA; CAB022093; -.
DR   HPA; HPA057265; -.
DR   HPA; HPA064297; -.
DR   MIM; 180410; gene.
DR   neXtProt; NX_P23921; -.
DR   OpenTargets; ENSG00000167325; -.
DR   PharmGKB; PA298; -.
DR   eggNOG; KOG1112; Eukaryota.
DR   eggNOG; COG0209; LUCA.
DR   GeneTree; ENSGT00390000001372; -.
DR   HOGENOM; HOG000057035; -.
DR   HOVERGEN; HBG003447; -.
DR   InParanoid; P23921; -.
DR   KO; K10807; -.
DR   OMA; KMTEIPD; -.
DR   OrthoDB; EOG091G01XV; -.
DR   PhylomeDB; P23921; -.
DR   TreeFam; TF300578; -.
DR   BioCyc; MetaCyc:HS09541-MONOMER; -.
DR   BRENDA; 1.17.4.1; 2681.
DR   Reactome; R-HSA-499943; Synthesis and interconversion of nucleotide di- and triphosphates.
DR   UniPathway; UPA00326; -.
DR   ChiTaRS; RRM1; human.
DR   EvolutionaryTrace; P23921; -.
DR   GeneWiki; RRM1; -.
DR   GenomeRNAi; 6240; -.
DR   PRO; PR:P23921; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000167325; -.
DR   CleanEx; HS_RRM1; -.
DR   ExpressionAtlas; P23921; baseline and differential.
DR   Genevisible; P23921; HS.
DR   GO; GO:0042995; C:cell projection; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005635; C:nuclear envelope; IEA:Ensembl.
DR   GO; GO:0005971; C:ribonucleoside-diphosphate reductase complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0097718; F:disordered domain specific binding; IEA:Ensembl.
DR   GO; GO:0004748; F:ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor; ISS:UniProtKB.
DR   GO; GO:0021846; P:cell proliferation in forebrain; IEA:Ensembl.
DR   GO; GO:0009263; P:deoxyribonucleotide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; IEA:UniProtKB-UniPathway.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0000278; P:mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0015949; P:nucleobase-containing small molecule interconversion; TAS:Reactome.
DR   GO; GO:0051290; P:protein heterotetramerization; IEA:Ensembl.
DR   GO; GO:0006206; P:pyrimidine nucleobase metabolic process; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   InterPro; IPR005144; ATP-cone_dom.
DR   InterPro; IPR013346; NrdE_NrdA.
DR   InterPro; IPR000788; RNR_lg_C.
DR   InterPro; IPR013509; RNR_lsu_N.
DR   InterPro; IPR008926; RNR_R1-su_N.
DR   Pfam; PF03477; ATP-cone; 1.
DR   Pfam; PF02867; Ribonuc_red_lgC; 1.
DR   Pfam; PF00317; Ribonuc_red_lgN; 1.
DR   PRINTS; PR01183; RIBORDTASEM1.
DR   SUPFAM; SSF48168; SSF48168; 1.
DR   TIGRFAMs; TIGR02506; NrdE_NrdA; 1.
DR   PROSITE; PS51161; ATP_CONE; 1.
DR   PROSITE; PS00089; RIBORED_LARGE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; ATP-binding;
KW   Complete proteome; Cytoplasm; Disulfide bond; DNA replication;
KW   Nucleotide-binding; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    792       Ribonucleoside-diphosphate reductase
FT                                large subunit.
FT                                /FTId=PRO_0000187190.
FT   DOMAIN        1     92       ATP-cone. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00492}.
FT   REGION       11     17       Allosteric activator binding.
FT                                {ECO:0000250}.
FT   REGION      217    218       Substrate binding. {ECO:0000250}.
FT   REGION      285    288       Allosteric effector binding, determines
FT                                substrate specificity.
FT   REGION      427    431       Substrate binding. {ECO:0000250}.
FT   REGION      603    607       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    427    427       Proton acceptor. {ECO:0000250}.
FT   ACT_SITE    429    429       Cysteine radical intermediate.
FT                                {ECO:0000250}.
FT   ACT_SITE    431    431       Proton acceptor. {ECO:0000250}.
FT   BINDING       5      5       Allosteric activator. {ECO:0000250}.
FT   BINDING      53     53       Allosteric activator. {ECO:0000250}.
FT   BINDING      88     88       Allosteric activator. {ECO:0000250}.
FT   BINDING     202    202       Substrate. {ECO:0000250}.
FT   BINDING     247    247       Substrate; via amide nitrogen.
FT                                {ECO:0000250}.
FT   SITE        218    218       Important for hydrogen atom transfer.
FT                                {ECO:0000250}.
FT   SITE        226    226       Allosteric effector binding, determines
FT                                substrate specificity.
FT   SITE        256    256       Allosteric effector binding, determines
FT                                substrate specificity.
FT   SITE        444    444       Important for hydrogen atom transfer.
FT                                {ECO:0000250}.
FT   SITE        737    737       Important for electron transfer.
FT                                {ECO:0000250}.
FT   SITE        738    738       Important for electron transfer.
FT                                {ECO:0000250}.
FT   SITE        787    787       Interacts with thioredoxin/glutaredoxin.
FT                                {ECO:0000250}.
FT   SITE        790    790       Interacts with thioredoxin/glutaredoxin.
FT                                {ECO:0000250}.
FT   MOD_RES      17     17       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     376    376       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     751    751       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   DISULFID    218    444       Redox-active. {ECO:0000250}.
FT   VARIANT     590    590       K -> Q (in dbSNP:rs2228123).
FT                                /FTId=VAR_052052.
FT   VARIANT     778    778       V -> A (in dbSNP:rs2229196).
FT                                /FTId=VAR_052053.
FT   MUTAGEN      57     57       D->N: Severely decreases interaction with
FT                                AHCYL1 in the presence of dATP.
FT                                {ECO:0000269|PubMed:25237103}.
FT   CONFLICT      6      6       R -> Q (in Ref. 3; AAD37491).
FT                                {ECO:0000305}.
FT   STRAND        2      4       {ECO:0000244|PDB:3HNC}.
FT   STRAND       10     12       {ECO:0000244|PDB:3HNC}.
FT   HELIX        15     23       {ECO:0000244|PDB:3HNC}.
FT   TURN         31     33       {ECO:0000244|PDB:3HNC}.
FT   HELIX        36     44       {ECO:0000244|PDB:3HNC}.
FT   STRAND       48     50       {ECO:0000244|PDB:3HND}.
FT   HELIX        53     66       {ECO:0000244|PDB:3HNC}.
FT   HELIX        67     69       {ECO:0000244|PDB:3HNC}.
FT   HELIX        78     88       {ECO:0000244|PDB:2WGH}.
FT   HELIX        94    103       {ECO:0000244|PDB:2WGH}.
FT   TURN        107    109       {ECO:0000244|PDB:2WGH}.
FT   HELIX       118    126       {ECO:0000244|PDB:2WGH}.
FT   HELIX       128    133       {ECO:0000244|PDB:2WGH}.
FT   HELIX       137    142       {ECO:0000244|PDB:2WGH}.
FT   HELIX       145    154       {ECO:0000244|PDB:2WGH}.
FT   STRAND      158    163       {ECO:0000244|PDB:3HNF}.
FT   HELIX       167    179       {ECO:0000244|PDB:2WGH}.
FT   HELIX       183    195       {ECO:0000244|PDB:2WGH}.
FT   STRAND      197    200       {ECO:0000244|PDB:2WGH}.
FT   HELIX       202    207       {ECO:0000244|PDB:2WGH}.
FT   STRAND      210    212       {ECO:0000244|PDB:2WGH}.
FT   STRAND      218    222       {ECO:0000244|PDB:2WGH}.
FT   HELIX       228    243       {ECO:0000244|PDB:2WGH}.
FT   STRAND      247    251       {ECO:0000244|PDB:2WGH}.
FT   STRAND      258    261       {ECO:0000244|PDB:3HNE}.
FT   HELIX       263    265       {ECO:0000244|PDB:2WGH}.
FT   STRAND      268    270       {ECO:0000244|PDB:3HNE}.
FT   HELIX       272    285       {ECO:0000244|PDB:2WGH}.
FT   STRAND      287    293       {ECO:0000244|PDB:3HND}.
FT   STRAND      297    301       {ECO:0000244|PDB:2WGH}.
FT   HELIX       308    311       {ECO:0000244|PDB:2WGH}.
FT   TURN        312    315       {ECO:0000244|PDB:2WGH}.
FT   STRAND      317    319       {ECO:0000244|PDB:2WGH}.
FT   HELIX       321    323       {ECO:0000244|PDB:2WGH}.
FT   STRAND      328    334       {ECO:0000244|PDB:2WGH}.
FT   HELIX       336    343       {ECO:0000244|PDB:2WGH}.
FT   STRAND      347    351       {ECO:0000244|PDB:2WGH}.
FT   TURN        353    355       {ECO:0000244|PDB:2WGH}.
FT   HELIX       359    361       {ECO:0000244|PDB:2WGH}.
FT   HELIX       365    376       {ECO:0000244|PDB:2WGH}.
FT   STRAND      381    385       {ECO:0000244|PDB:2WGH}.
FT   HELIX       386    400       {ECO:0000244|PDB:2WGH}.
FT   STRAND      404    407       {ECO:0000244|PDB:2WGH}.
FT   HELIX       408    413       {ECO:0000244|PDB:2WGH}.
FT   HELIX       418    420       {ECO:0000244|PDB:2WGH}.
FT   STRAND      428    430       {ECO:0000244|PDB:3HNC}.
FT   STRAND      442    444       {ECO:0000244|PDB:2WGH}.
FT   STRAND      446    450       {ECO:0000244|PDB:2WGH}.
FT   HELIX       451    454       {ECO:0000244|PDB:2WGH}.
FT   STRAND      459    461       {ECO:0000244|PDB:3HND}.
FT   HELIX       463    483       {ECO:0000244|PDB:2WGH}.
FT   HELIX       489    498       {ECO:0000244|PDB:2WGH}.
FT   STRAND      502    506       {ECO:0000244|PDB:2WGH}.
FT   HELIX       508    514       {ECO:0000244|PDB:2WGH}.
FT   STRAND      519    521       {ECO:0000244|PDB:3HND}.
FT   HELIX       522    550       {ECO:0000244|PDB:2WGH}.
FT   HELIX       554    556       {ECO:0000244|PDB:3HNE}.
FT   HELIX       561    563       {ECO:0000244|PDB:2WGH}.
FT   HELIX       567    570       {ECO:0000244|PDB:2WGH}.
FT   STRAND      577    579       {ECO:0000244|PDB:2WGH}.
FT   HELIX       581    591       {ECO:0000244|PDB:2WGH}.
FT   HELIX       607    611       {ECO:0000244|PDB:2WGH}.
FT   STRAND      623    629       {ECO:0000244|PDB:3HNC}.
FT   STRAND      632    637       {ECO:0000244|PDB:3HNC}.
FT   HELIX       639    648       {ECO:0000244|PDB:2WGH}.
FT   HELIX       655    661       {ECO:0000244|PDB:2WGH}.
FT   TURN        662    664       {ECO:0000244|PDB:3HNC}.
FT   STRAND      670    672       {ECO:0000244|PDB:2WGH}.
FT   HELIX       674    679       {ECO:0000244|PDB:2WGH}.
FT   TURN        683    685       {ECO:0000244|PDB:3HNC}.
FT   HELIX       688    699       {ECO:0000244|PDB:2WGH}.
FT   HELIX       717    729       {ECO:0000244|PDB:2WGH}.
FT   STRAND      733    737       {ECO:0000244|PDB:2WGH}.
SQ   SEQUENCE   792 AA;  90070 MW;  4470A76C61E8F86A CRC64;
     MHVIKRDGRQ ERVMFDKITS RIQKLCYGLN MDFVDPAQIT MKVIQGLYSG VTTVELDTLA
     AETAATLTTK HPDYAILAAR IAVSNLHKET KKVFSDVMED LYNYINPHNG KHSPMVAKST
     LDIVLANKDR LNSAIIYDRD FSYNYFGFKT LERSYLLKIN GKVAERPQHM LMRVSVGIHK
     EDIDAAIETY NLLSERWFTH ASPTLFNAGT NRPQLSSCFL LSMKDDSIEG IYDTLKQCAL
     ISKSAGGIGV AVSCIRATGS YIAGTNGNSN GLVPMLRVYN NTARYVDQGG NKRPGAFAIY
     LEPWHLDIFE FLDLKKNTGK EEQRARDLFF ALWIPDLFMK RVETNQDWSL MCPNECPGLD
     EVWGEEFEKL YASYEKQGRV RKVVKAQQLW YAIIESQTET GTPYMLYKDS CNRKSNQQNL
     GTIKCSNLCT EIVEYTSKDE VAVCNLASLA LNMYVTSEHT YDFKKLAEVT KVVVRNLNKI
     IDINYYPVPE ACLSNKRHRP IGIGVQGLAD AFILMRYPFE SAEAQLLNKQ IFETIYYGAL
     EASCDLAKEQ GPYETYEGSP VSKGILQYDM WNVTPTDLWD WKVLKEKIAK YGIRNSLLIA
     PMPTASTAQI LGNNESIEPY TSNIYTRRVL SGEFQIVNPH LLKDLTERGL WHEEMKNQII
     ACNGSIQSIP EIPDDLKQLY KTVWEISQKT VLKMAAERGA FIDQSQSLNI HIAEPNYGKL
     TSMHFYGWKQ GLKTGMYYLR TRPAANPIQF TLNKEKLKDK EKVSKEEEEK ERNTAAMVCS
     LENRDECLMC GS
//
